vs
Side-by-side financial comparison of Celularity Inc (CELU) and DeFi Development Corp. (DFDV). Click either name above to swap in a different company.
Celularity Inc is the larger business by last-quarter revenue ($5.3M vs $4.6M, roughly 1.1× DeFi Development Corp.). DeFi Development Corp. runs the higher net margin — 1211.4% vs -436.7%, a 1648.1% gap on every dollar of revenue. On growth, DeFi Development Corp. posted the faster year-over-year revenue change (647.2% vs -43.2%). Over the past eight quarters, DeFi Development Corp.'s revenue compounded faster (181.5% CAGR vs -33.9%).
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
Automotive Design and Development Ltd (ADD) was an English company responsible for the creation of the futuristic-looking Nova kit car. It was based in Southampton from 1971 to 1973 after which it moved to Accrington, Lancashire until 1975. ADD failed and the rights to the Nova were bought by Nova Cars in Mirfield, West Yorkshire in 1978, which continued until 1990. A low volume production run was made by Nova Developments in Cornwall in the 1990s and the company was sold to India-based Aerot...
CELU vs DFDV — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $5.3M | $4.6M |
| Net Profit | $-23.1M | $56.0M |
| Gross Margin | 26.1% | 98.1% |
| Operating Margin | -244.1% | — |
| Net Margin | -436.7% | 1211.4% |
| Revenue YoY | -43.2% | 647.2% |
| Net Profit YoY | -43.3% | 11995.1% |
| EPS (diluted) | $-0.88 | $1.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $5.3M | $4.6M | ||
| Q2 25 | $5.7M | $2.0M | ||
| Q1 25 | $11.4M | $287.2K | ||
| Q4 24 | $18.1M | $628.9K | ||
| Q3 24 | $9.3M | $619.0K | ||
| Q2 24 | $12.1M | $441.0K | ||
| Q1 24 | $14.7M | $411.1K | ||
| Q4 23 | $12.1M | — |
| Q3 25 | $-23.1M | $56.0M | ||
| Q2 25 | $-24.5M | $15.4M | ||
| Q1 25 | $-19.8M | $-778.0K | ||
| Q4 24 | $-13.3M | $-487.0K | ||
| Q3 24 | $-16.1M | $-471.0K | ||
| Q2 24 | $-6.5M | $-805.0K | ||
| Q1 24 | $-22.0M | $-964.0K | ||
| Q4 23 | $9.5M | — |
| Q3 25 | 26.1% | 98.1% | ||
| Q2 25 | 8.6% | 98.6% | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | 98.8% | ||
| Q3 24 | 58.2% | 98.7% | ||
| Q2 24 | 82.5% | 98.2% | ||
| Q1 24 | 88.8% | 97.9% | ||
| Q4 23 | 20.7% | — |
| Q3 25 | -244.1% | — | ||
| Q2 25 | -276.6% | — | ||
| Q1 25 | -91.8% | -307.5% | ||
| Q4 24 | -51.2% | -107.9% | ||
| Q3 24 | -124.0% | -73.3% | ||
| Q2 24 | -84.0% | -193.2% | ||
| Q1 24 | -50.2% | -247.7% | ||
| Q4 23 | — | — |
| Q3 25 | -436.7% | 1211.4% | ||
| Q2 25 | -427.5% | 777.0% | ||
| Q1 25 | -172.9% | -270.9% | ||
| Q4 24 | -73.3% | -77.4% | ||
| Q3 24 | -173.2% | -76.1% | ||
| Q2 24 | -53.6% | -182.5% | ||
| Q1 24 | -149.9% | -234.5% | ||
| Q4 23 | 78.8% | — |
| Q3 25 | $-0.88 | $1.95 | ||
| Q2 25 | $-1.02 | $0.84 | ||
| Q1 25 | $-0.84 | $-0.55 | ||
| Q4 24 | $-0.58 | $0.55 | ||
| Q3 24 | $-0.73 | $-0.05 | ||
| Q2 24 | $-0.30 | $-0.08 | ||
| Q1 24 | $-1.03 | $-0.70 | ||
| Q4 23 | $0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0K | $1.4M |
| Total DebtLower is stronger | $35.7M | $131.4M |
| Stockholders' EquityBook value | $-20.1M | $243.8M |
| Total Assets | $114.2M | $480.0M |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $120.0K | $1.4M | ||
| Q2 25 | $863.0K | $595.0K | ||
| Q1 25 | $293.0K | $2.2M | ||
| Q4 24 | $738.0K | $2.8M | ||
| Q3 24 | $133.0K | $2.8M | ||
| Q2 24 | $467.0K | $3.2M | ||
| Q1 24 | $1.9M | $3.9M | ||
| Q4 23 | $227.0K | — |
| Q3 25 | $35.7M | $131.4M | ||
| Q2 25 | — | $21.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | $-20.1M | $243.8M | ||
| Q2 25 | $-25.5M | $79.6M | ||
| Q1 25 | $-5.5M | $2.8M | ||
| Q4 24 | $8.8M | $3.5M | ||
| Q3 24 | $17.3M | $4.0M | ||
| Q2 24 | $27.8M | $4.3M | ||
| Q1 24 | $31.2M | $5.0M | ||
| Q4 23 | $41.0M | — |
| Q3 25 | $114.2M | $480.0M | ||
| Q2 25 | $120.3M | $107.2M | ||
| Q1 25 | $128.9M | $4.2M | ||
| Q4 24 | $132.7M | $4.4M | ||
| Q3 24 | $128.8M | $4.5M | ||
| Q2 24 | $135.5M | $4.8M | ||
| Q1 24 | $143.8M | $5.5M | ||
| Q4 23 | $143.9M | — |
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-5.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | -0.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.2M | $-5.0M | ||
| Q2 25 | $-999.0K | $-1.3M | ||
| Q1 25 | $-3.0M | $-785.6K | ||
| Q4 24 | $1.6M | $-2.4M | ||
| Q3 24 | $-144.0K | $-412.0K | ||
| Q2 24 | $-3.4M | $-680.8K | ||
| Q1 24 | $-4.4M | $-1.1M | ||
| Q4 23 | $-4.3M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.5M | $-2.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-3.5M | $-687.4K | ||
| Q1 24 | $-4.4M | $-1.2M | ||
| Q4 23 | $-4.9M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 8.3% | -388.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | -28.7% | -155.9% | ||
| Q1 24 | -30.3% | -280.3% | ||
| Q4 23 | -40.6% | — |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.5% | 3.7% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.3% | 1.5% | ||
| Q1 24 | 0.3% | 1.6% | ||
| Q4 23 | 4.8% | — |
| Q3 25 | — | -0.09× | ||
| Q2 25 | — | -0.08× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -0.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
DFDV
| Digital Asset Treasury | $3.8M | 82% |
| Other | $831.0K | 18% |
